Pan-cancer analysis reveals PRRT4 is a potential prognostic factor of AML

Proline-rich transmembrane protein 4 (PRRT4) has been infrequently studied, with limited literature suggesting its potential as a prognostic marker for gastric cancer. This study aims to investigate the prognostic value of the PRRT4 gene in pan-cancer. We acquired and analyzed data from several platforms, including The Cancer Genome Atlas (TCGA), Genotype Tissue Expression Project (GTEx), Cancer Cell Line Encyclopedia (CCLE), cBioPortal, HPA, and TIMER 2.0. In addition, we have further analyzed the data using multivariate analyzes and RT-qPCR. In vitro experiments were performed to detect the proliferation and apoptosis of AML cells before and after PRRT4 knockdown. PRRT4 exhibited low expression in 10 types of cancers and high expression in 3 types, and this expression was significantly correlated with tumor stage, age, and gender across various cancer types. PRRT4, identified as a potential independent prognostic factor for overall survival (OS) in several cancers including LAML, PAAD, SKCM, STAD, THYM, and UVM, and exhibited a high frequency of mutation in UCEC. Moreover, PRRT4 was found to be correlated with DNA methylation and immune infiltration in various cancers. Ultimately, in the multivariate analysis model, PRRT4 was discerned as an independent prognostic biomarker for AML, predicated on the statistics based from our institution. After PRRT4 knockdown, the proliferation ability of THP1 cells was significantly enhanced, and the apoptosis ratio was significantly decreased. PRRT4 may serve as a potential therapeutic target and prognostic marker for various malignancies. This study comprehensively analyzed the expression of PRRT4 in 33 cancers through data from multiple databases, and further analyzed the relationship between PRRT4 expression and patients' clinical characteristics, prognosis, gene mutation, immune status, TMB, MSI, and DNA methylation. Results suggest that PRRT4 is a potential independent prognostic predictor for a variety of cancers, including LAML, PAAD, SKCM, STAD, THYM, and UVM. Based on this, we examined the expression of PRRT4 in our previously included leukemia clinical samples, and the results of univariate and multivariate analysis showed that PRRT4 was an independent prognostic factor in leukemia patients. After PRRT4 knockdown, the proliferation ability of THP1 cells was significantly enhanced, and the apoptosis ratio was significantly decreased.